# Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

> **NCT02462486** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 949 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Abicipar Pegol
- **DRUG:** Ranibizumab
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT02462486
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-25
- **Primary completion:** 2018-04-12
- **Final completion:** 2019-06-06
- **Target enrollment:** 949 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462486, "Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02462486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*